**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5866**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer**

Takeda A *et al*SBRT for oligometastasis from CRC

Atsuya Takeda, Naoko Sanuki, Etsuo Kunieda

**Atsuya Takeda, Naoko Sanuki,** Radiation Oncology Center, Ofuna Chuo Hospital, Kanagawa 247-0056, Japan

**Etsuo Kunieda,** Department of Radiation Oncology, Tokai University, Kanagawa 259-1193 Japan

**Author contributions:** Takeda A contributed to the manuscript idea, literature search, manuscript writing, and final revision of the article; Sanuki N contributed to the manuscript idea and the final revision of the article; Kunieda E contributed to the final revision of the article.

**Correspondence to: Atsuya Takeda, MD, PhD,** Radiation Oncology Center, Ofuna Chuo Hospital, 6-2-24, Ofuna, Kamakura, Kanagawa 247-0056, Japan. takeda@1994.jukuin.keio.ac.jp

**Telephone:** +81-467-452111 **Fax:** +81-467-483197

**Received:** September 27, 2013  **Revised:** December 24, 2013

**Accepted:** February 20, 2014

**Published online**

**Abstract**

Systemic chemotherapy has enabled prolongation of survival in patients with stage IV colorectal cancer. This has subsequently increased the relative significance of local therapy for patients with oligometastases because they can be cured by removal of oligometastatic lesions. One of the most frequently reported tumor histologies for oligometastases is colorectal cancer. Resection is the standard therapy in most settings of oligometastases. Recently, studies have shown that stereotactic body radiotherapy (SBRT) may become a treatment option that provides high local control with minimal morbidity. Two-year local control rates following SBRT for hepatic and pulmonary oligometastases are almost over 80% and are even higher for patients treated with high-dose regimens. The indications of SBRT for other metastatic sites or conditions include isolated lymph nodes, spinal and adrenal metastasis, and post-surgical pelvic recurrence. Many retrospective studies have indicated that SBRT for various lesions results in good outcomes with low morbidity, both in the curative and palliative setting. However, few reports with a high level of evidence have indicated the efficacy of SBRT compared to standard therapy. Hereafter, the optimal indication of SBRT needs to be prospectively investigated to obtain convincing evidence.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Oligometastasis; Colorectal cancer; Radiation therapy; Stereotactic ablation body radiation therapy; Local therapy

**Core tip**: Systemic chemotherapy has enabled prolongation of survival in patients with stage IV colorectal cancer. This has subsequently increased the relative significance of local therapy. Resection is the standard therapy in most settings. Recently, stereotactic body radiotherapy (SBRT) provides high local control with minimal morbidity, both in the curative and palliative setting. The indications of SBRT include liver, lung, isolated lymph nodes, spinal and adrenal metastasis, and post-surgical pelvic recurrence. However, few reports with a high level of evidence have indicated the efficacy of SBRT. Hereafter, the optimal indication of SBRT needs to be prospectively investigated to obtain convincing evidence.

Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. *World J Gastroenterol* 2014;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v20.i0.0000**INTRODUCTION**

Colorectal cancer (CRC) is currently the second- or third-leading cause of death from cancer in both genders, and its frequency continues to increase[[1](#_ENREF_1),[2](#_ENREF_2)]. Although there exist somewhat different characteristics between colon cancer and rectal cancer[[3](#_ENREF_3),[4](#_ENREF_4)], most articles investigated them together. Among patients with CRC, 20% have metastases at initial presentation, and an additional 25%–50% develop metastases after treatment of early-stage disease. Among patients with an initial finding of metastasis, 50% will have disease limited to the liver, and at the time of death, 20% have liver metastasis only[[5](#_ENREF_5)]. Rates of metastases are 60%–71% in the liver, 25%–40% in the lung, 5%–10% in bones, 3%–5% in the ovary, 1% in the adrenal gland, and 1% in the central nervous system[[6](#_ENREF_6)].

Since the late 1990s, development of new agents such as irinotecan, oxaliplatin, and biologic agents targeting either epidermal growth factor receptor or vascular endothelial growth factor has greatly prolonged progression-free survival and overall survival in stage IV CRC patients[[7](#_ENREF_7),[8](#_ENREF_8)]. Such prolongation of survival attributed to chemotherapy has increased the relative significance of local therapy for patients with limited metastases. An increasing amount of data suggests that curative resection of isolated metastases yields a survival benefit regardless of whether the metastatic site is the liver[[9](#_ENREF_9),[10](#_ENREF_10)], lung[[11](#_ENREF_11),[12](#_ENREF_12)], peritoneum[[13](#_ENREF_13),[14](#_ENREF_14)], ovary[[15](#_ENREF_15),[16](#_ENREF_16)], or extra-regional lymph nodes[[17](#_ENREF_17),[18](#_ENREF_18)]. Although complete surgical resection of these metastases does not result in long-term survival in all patients, select patients can survive for a relatively long period without recurrence.

Stereotactic body radiotherapy (SBRT) is a high-precision conformal external-beam radiation technique that ablates the target at extracranial sites with hypofractionated high-dose radiation while sparing the surrounding normal tissue. SBRT results in minimal morbidity and provides high local control rates for medically inoperable stage I non-small-cell lung cancer (NSCLC)[[19](#_ENREF_19)]. Currently, SBRT is considered to be a treatment option for patients with medically inoperable, early-stage NSCLC[[20](#_ENREF_20)]. However, few adequate studies have evaluated SBRT for pulmonary oligometastases from CRC[[21](#_ENREF_21)]. In this article, we review the clinical outcomes of SBRT for oligometastases from CRC and discuss the role of SBRT in oligometastasis treatment in general.

**CONCEPT OF OLIGOMETASTASIS**

Hellman *et al*[[22](#_ENREF_22)] ﬁrst proposed the idea of an oligometastatic state in 1995. These authors suggested that initially, a few metastases from various cancers exist, before the malignant cells acquire widespread metastatic potential. The term oligometastases indicates an intermediate state of cancer that lies between localized disease and widespread metastases. Metastases from solid tumors are regarded as being representative of disseminated cancer and are not considered to be curable. In contrast, evidence has emerged that patients with oligometastases can be cured by resection of these lesions. The most frequently reported tumor histologies in one surgical series of oligometastases were CRC and sarcoma[[23](#_ENREF_23)]. Resection of liver metastases from CRC patients resulted in 5-year survival rates of 25%–50%[[24-26](#_ENREF_24)], and a large series of more than 1,000 patients reported a 10-year overall survival rate of 22%[[27](#_ENREF_27)]. Among resection survivors who lived for 10 years, Tomlinson *et al*[[28](#_ENREF_28)] demonstrated high disease-speciﬁc survival, with only 1 cancer death among 102 patients, reinforcing the concept that this group was truly cured of cancer.

For patients with oligometastases from CRC, non-invasive local therapy is appropriate because they are already receiving systematic chemotherapy, are often frail, and may survive only a short time. In addition to resection, local ablation therapies such as cryoablation and radiofrequency ablation (RFA) have been reported to be feasible treatment options. SBRT may become a more suitable treatment option for these patients, because less morbidity occurs following SBRT than that following RFA[[29](#_ENREF_29)] and resection.

**CONVENTIONAL RADIOTHERAPY AND SBRT**

Conventional radiotherapy (*i.e.*, 1.8–2.0 Gy per fraction) results in a tumoricidal effect by means of mitotic death of cancer cells, allowing simultaneous recovery of late sublethal damage of normal tissues. In contrast, SBRT may provide a novel mechanism of radiation-induced damage: data with higher doses per fraction (*i.e.*, 10–20 Gy per fraction) suggest that, in addition to direct cytotoxicity, a different mechanism involving microvascular damage begins to have a substantial effect on the tumor cell kill[[30](#_ENREF_30),[31](#_ENREF_31)]. Endothelial apoptosis results in microvascular disruption and death of the tissue supplied by that vasculature[[30](#_ENREF_30)] .

Over 1 decade ago, conventional radiotherapy was offered to medically inoperable patients with stage I NSCLC. The prescribed doses of 60–75 Gy per 1.8–2 Gy fractions were administered to these patients. However, those doses were determined based on critical doses of serious radiation pneumonitis rather than sufficient doses to achieve high local control of primary lesions. Therefore, the 5-year local control and overall survival rates were insufficient (40% and 21%, respectively)[[32](#_ENREF_32)]. In contrast, SBRT enables delivery of sufficiently high doses to a target volume and omission of unnecessary doses to surrounding normal lung tissue. Therefore, 5-year local control and overall survival rates associated with SBRT are relatively high (> 90% and 42%, respectively)[[33](#_ENREF_33)]. Currently, SBRT is an established treatment option for medically inoperable patients with stage I NSCLC. Furthermore, a propensity score-matched analysis revealed superior local control and comparable overall survival of SBRT compared to video-assisted thoracoscopic surgery[[34](#_ENREF_34)]. In addition, SBRT appears to be less costly than surgery[[35](#_ENREF_35)]. Quality of life also appears to favor SBRT, because no statistically or clinically significant worsening of any quality of life functioning or symptom scores has been observed in patients with stage I NSCLC treated with SBRT[[36](#_ENREF_36)]. In contrast, quality of life has been shown to be significantly impaired after surgery. Randomized, controlled trials to compare SBRT to resection are therefore needed.

The liver is thought to be a relatively radiosensitive organ. It was difficult to irradiate with a sufficient dose to eradicate tumors without causing lethal radiation-induced liver disease. Therefore, conventional radiotherapy has played a very limited role in the treatment of hepatocellular carcinoma[[37](#_ENREF_37)]. In contrast, reports of SBRT for hepatocellular carcinoma have been steadily increasing since 2006. Although the SBRT literature primarily consists of retrospective, small, single-institution series, SBRT has been associated with high local control rates, most in the range of 70%–90% at 1–2 years[[38-40](#_ENREF_38)]. In a retrospective analysis of previously untreated hepatocellular carcinoma, SBRT yielded a 3-year overall survival rate of 73%, which is comparable to that of a series treated with surgery or RFA[[41](#_ENREF_41)].

As for NSCLC and hepatocellular carcinoma, SBRT is expected to play a role in the treatment of oligometastases from CRC. However, negative factors also exist: for example, CRC metastases contain larger proportions of hypoxic cells compared to other tumor types[[42](#_ENREF_42)], and hypoxia leads to a decrease in radiosensitivity; another is that microscopic extension of oligometastases from CRC may compromise local control[[43](#_ENREF_43)]. In fact, the local control rates of SBRT in CRC oligometastases are significantly worse than those of oligometastases from other cancers, including NSCLC. Thus, dose escalation should be considered to achieve better local control[[44](#_ENREF_44)].

**SBRT FOR OLIGOMETASTASES BY SITE**

Several studies have investigated SBRT for oligometastases. However, these have been retrospective and included small sample sizes. Furthermore, patients in these studies were affected by a variety of primary cancers in addition to CRC. Therefore, it is difficult to refer to the outcome of SBRT for oligometastases from CRC exclusively.

**LIVER METASTASIS**

Combination chemotherapy and resection of liver metastases has been used to manage patients with confined liver metastasis from CRC. According to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network (NCCN), resection is the mainstay of treatment for CRC patients with liver metastases only[[45](#_ENREF_45)]. This combined therapy has resulted in 5-year survival rates of 25%–50%[[24-26](#_ENREF_24)]. The cumulative 3-year local recurrence-free survival rate following resection of solitary liver metastases was reported to be 88%-95%[[46](#_ENREF_46),[47](#_ENREF_47)]. However, hepatic metastases are resectable in only about 20% of patients[[48](#_ENREF_48)]. For the remaining 80% of patients, resection is contraindicated due to the presence of diffuse hepatic metastases, non-resectable extrahepatic disease, or impaired liver function.

Several technical improvements have been made in diagnostic assessment and treatment strategies for CRC hepatic metastases. For example, modern computed tomography (CT), magnetic resonance imaging, and positron-emission tomography-CT techniques enable accurate diagnosis and staging. Furthermore, surgical dissection techniques and potent systemic chemotherapy protocols have been optimized. As a result, even patients with > 3 metastases or with metastases > 5 cm in diameter can be cured with appropriate surgical treatment[[28](#_ENREF_28)].

Resectability is often limited by an unfavorable anatomical metastatic site, poor function of the remaining hepatic parenchyma, and/or poor general patient condition. Postoperative hepatic function can be predicted more precisely with the aid of CT volumetry. This technique enables prediction of the remaining volume of hepatic tissue after surgery to within 10% of the actual value. Metastases are considered resectable[[49](#_ENREF_49)] when the following criteria are met: (1) exclusion of a non-resectable extrahepatic tumor manifestation; (2) parenchymal involvement < 75%; (3) < 3 hepatic veins and < 7 hepatic segments involved; (4) no hepatic insufficiency, *i.e.*, no Child B or C cirrhosis; and (5) no severe accompanying diseases.

Retrospective studies of SBRT in patients with medically or technically unresectable liver metastases have been performed. Table 1 shows the outcomes of SBRT for liver metastasis from CRC and other origins[[50-58](#_ENREF_50)]. Various prescribed doses of SBRT were used in these studies. The 2-year local control rates were almost over 80% and were higher for patients treated with high-dose regimens in two studies[[51](#_ENREF_51),[57](#_ENREF_57)]. The 2-year overall survival rates varied from 32%–83%. It is important to note that these outcomes may depend on biased patient selection. And yet, little toxicity was observed.

 As a local treatment, the use of RFA is controversial. Most centers only ablate tumors in those patients who are deemed unresectable. Patients with large, poorly placed tumors have the highest likelihood of recurrence, regardless of therapy. Retrospective analyses of RFA for liver metastases from CRC have shown broad variability in 2-year local control rates, ranging from 32%–76%[[46](#_ENREF_46),[59-61](#_ENREF_59)], and in 5-year overall survival rates, ranging from 14%–55%[[46](#_ENREF_46),[61](#_ENREF_61)]. A meta-analysis revealed that RFA yielded a higher rate of local intrahepatic recurrence compared to resection (odds ratio: 4.89), although a selection bias was noted[[62](#_ENREF_62)].

**PULMONARY METASTASIS**

As chemotherapeutic and biological agents have considerably improved outcomes in patients with stage IV CRC, resection of pulmonary oligometastases is increasingly performed with curative intent. In the NCCN Clinical Practice Guidelines, pulmonary resection is recommended as well as hepatic oligometastatic resection[[45](#_ENREF_45)]. However, no prospective randomized studies have been performed to validate the efficacy of resection in this setting. Therefore, it is currently not possible to identify which CRC patients may beneﬁt most from this surgical strategy[[63](#_ENREF_63)].

A meta-analysis revealed that factors correlated with better survival included a prolonged disease-free interval between primary tumor and metastatic spread, normal pre-thoracotomy carcinoembryonic antigen levels, absence of thoracic node involvement, and a single pulmonary lesion[[64](#_ENREF_64)]. Of 44 patients with ≥ 3 lesions and a < 1-year disease-free interval, 0 were cured by surgery. In contrast, recurrence-free survival was 49% at 3 years for patients with 1 lesion and a disease-free interval > 1 year. Therefore, medical management alone should be considered standard for patients who have ≥ 3 pulmonary metastases and a < 1-year disease-free interval[[65](#_ENREF_65)].

Crude local recurrence rates following resection of oligometastasis from CRC have been reported to be 19.5%–28%[[66-68](#_ENREF_66)]. Local recurrence may occur even in cases with pathologically negative margins[[69](#_ENREF_69)]. A wide surgical margin around oligometastasis from CRC is required to prevent local recurrence, because satellite tumor cells are often present[[68](#_ENREF_68)].

For medically inoperable patients with limited pulmonary metastases from CRC, SBRT may be administered. Table 2 shows the outcomes of SBRT for pulmonary metastases from CRC and other origins[[44](#_ENREF_44),[70-80](#_ENREF_70)]. SBRT was given at various prescribed doses. The local control rates were almost over 80%, and the 2-year overall survival rates ranged from 33%–86%. These outcomes may have depended on patient selection. With respect to toxicities, grade ≥ 3 radiation pneumonitis was observed in only 0%–8% of patients. No other toxicities were observed.

Widder *et al*[[78](#_ENREF_80)] compared outcomes after SBRT with those after pulmonary metastasectomy in patients with pulmonary oligometastasis. In their institution, patients were offered pulmonary metastasectomy as the ﬁrst choice and SBRT in cases that they considered to be less suitable surgical candidates. Patients treated with SBRT had more unfavorable prognostic factors: they were significantly older, had a shorter metastasis-free interval, and a different distribution of primary tumor origins; thus, they were regarded as having a worse prognosis overall. Despite this selection bias, survival after SBRT was no worse than that after pulmonary metastasectomy. Prospective comparative studies are therefore required to deﬁne the role of both SBRT and pulmonary metastasectomy in oligometastatic disease.

 Among minimal ablation techniques, RFA is the most frequently used method for pulmonary oligometastasis. In a prospective multicenter trial[[81](#_ENREF_81)], RFA yielded a confirmed complete response rate of 88% (in both primary and metastatic lesions) and promising overall and cancer-specific survival outcomes. Retrospective analyses of RFA for pulmonary metastases from CRC have shown that the 2-year local control rates in all tumors, tumors < 3 cm, and tumors > 3 cm were 56%–80%, 69%–87%, and 19%–32%[[82](#_ENREF_82),[83](#_ENREF_83)], respectively, and that the 2-year overall survival rate was 34%–68%[[82-84](#_ENREF_82)].

**ISOLATED LYMPH NODE METASTASIS**

Retroperitoneal recurrence occurs in 15% of colon cancer cases and 5% of rectal cancer cases[[85](#_ENREF_85)], and isolated retroperitoneal recurrence occurs in approximately 1% of all CRC patients following curative surgery[[13](#_ENREF_13),[18](#_ENREF_18)]. Favorable results have been reported for curative surgical resection for isolated retroperitoneal lymph node recurrence of CRC[[13](#_ENREF_13),[18](#_ENREF_18)]. However the indication for resection is limited. Surgery for metastatic retroperitoneal lymph nodes is not feasible when (1) a recurrent retroperitoneal tumor is encased in or involves major vascular structures such as the superior mesenteric artery, celiac axis, and aorta; (2) the tumor invades adjacent organs such as the pancreas, bile duct, and duodenum; or (3) the patient has a poor performance status or comorbid disease[[13](#_ENREF_13),[18](#_ENREF_18)]. Even when lesions are localized, surgical resection is not widely accepted due to their relative rarity, high associated postoperative morbidity, and poor prognosis. In addition, the operative morbidity rate is high at 30%, which includes abscess, phlebitis, pneumonia, intestinal obstruction, and bladder leakage[[13](#_ENREF_13),[18](#_ENREF_18)].

The role of curative radiotherapy for isolated lymph node metastasis is also controversial. In a study that evaluated SBRT for isolated lymph node metastasis from CRC, preliminary results from 7 patients who received doses of 36–51 Gy in 3 fractions indicated local recurrence and Grade 4 intestinal obstruction in 1 patient each[[86](#_ENREF_86)]. Furthermore, the 3-year overall survival rate was 71%. The indication of SBRT in this setting is also limited because the lesions are often adjacent to the gastrointestinal tract. Considering the risk of gastrointestinal toxicities, conventional fractionated radiotherapy may be a better choice. Chemoradiotherapy with prescribed doses of 55.8bed Gy in 2020escribed doses of 55.8bed doses of 55.8 was 71%results, with a 3-year overall survival rate of 65% and no gastrointestinal toxicity ≥ Grade 3[[87](#_ENREF_87)].

**METASTASIS OF OTHER REGIONS**

SBRT has played a limited palliative role in the treatment of the sites described above, and may not contribute to improved survival. The indications of SBRT remain to be determined and should be considered based on the condition of each individual patient.

Among patients treated with radical surgery for rectal cancer, 20%–50% develop loco-regional recurrence[[88](#_ENREF_88),[89](#_ENREF_89)]. Most patients are not candidates for curative resection of recurrent pelvic disease, and even when radical surgery is possible, the 5-year survival rate after reoperation is < 35%. When no treatment is given, patients with locally recurrent rectal cancer have a median survival of ≤ 8 mo and suffer from severe symptoms, particularly pain, resulting in an extremely poor quality of life[[89-91](#_ENREF_89)]. In most patients, radiotherapy and chemotherapy provide only temporary symptom relief. Kim *et al*[[92](#_ENREF_92)] reported that 23 patients with recurrent rectal cancer were treated with SBRT at a median total dose of 39 (range, 30–51) Gy in 3 fractions. The 4-year overall survival and local control rates were 25% and 74%, respectively. Grade 4 rectal perforation was reported in 1 patient. Abusaris *et al*[[93](#_ENREF_93)] reported that symptom relief was observed in 96% in 27 patients who were re-irradiated with SBRT after conventional radiotherapy.

In patients with spinal metastasis, conventional radiotherapy is standard palliative therapy. In contrast, SBRT enables irradiation using a higher biologically effective dose compared to conventional radiotherapy. The goal of SBRT is, therefore, aimed at maximizing both local tumor and pain control. Local control appears to be excellent, with crude rates of 81%–94%[[94](#_ENREF_94)], although the prescribed doses vary significantly among series. A multi-institutional study revealed that caution must be used when treating with ≥ 20 Gy/fraction, particularly for patients with lytic tumors, spinal misalignment, and baseline vertebral compression fracture[[95](#_ENREF_95)].

The incidence of adrenal metastases from CRC is approximately 1%[[6](#_ENREF_6)]. With continuing progress in imaging techniques, an increasing number of adrenal metastases can be detected incidentally during follow-up or at the time of initial presentation. Open surgery represents the standard approach. Radiotherapy has been limited to palliation of painful adrenal metastases from lung cancer[[96](#_ENREF_96)]. Radiotherapy contributes to prolonged survival in these patients[[97](#_ENREF_97)]. Results of SBRT for adrenal metastasis from various origins have been reported: the 2-year local control rate was 32% with a median total dose of 32 Gy in 4 fractions[[98](#_ENREF_98)] and 90% with a median total dose of 36 Gy in 3 fractions [[99](#_ENREF_99)], without any ≥ Grade 3 toxicities.

**FUTURE PERSPECTIVE**

Many studies of SBRT for oligometastasis were retrospective and consisted of small sample sizes. In addition, patients in these studies were often affected by various types of primary cancer. We do not think the reasons for the small sample sizes and heterogeneous characteristics are uncommon indications or negative outcomes of SBRT for oligometastasis. In fact, these studies showed an improvement of survival and quality of life with low morbidity. In the future, we should evaluate whether SBRT is a valid treatment modality with a higher evidence level. For curative intent, dose escalation should be attempted for patients with pulmonary and hepatic oligometastasis to achieve better local control and subsequently to improve survival. SBRT outcomes may conceivably be comparable to those of surgery, with less morbidity in some patients. For palliative intent, optimal indications need to be defined. SBRT may have nearly equivalent efficacy compared to resection, with a shorter treatment duration and hospital stay, as well as a better quality of life. These questions should be addressed in future studies.

**CONCLUSION**

Many retrospective studies indicate that SBRT for various lesions achieves good outcomes with low morbidity, both in curative and palliative settings. However, few reports with a high evidence level have compared the efficacy of SBRT to that of standard therapy. Moving forward, we should prospectively investigate the indications for SBRT in robust studies.

**REFERENCES**

1 **Jemal A**, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA Cancer J Clin* 2007; **57**: 43-66 [PMID: 17237035]

2 **Verdecchia A**, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. *Lancet Oncol* 2007; **8**: 784-796 [PMID: 17714993 DOI: 10.1016/S1470-2045(07)70246-2]

3 **Kornmann M**, Staib L, Wiegel T, Kron M, Henne-Bruns D, Link KH, Formentini A. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer. *Clin Colorectal Cancer* 2013; **12**: 54-61 [PMID: 23107590 DOI: 10.1016/j.clcc.2012.07.005]

4 **Wang H**, Wei XZ, Fu CG, Zhao RH, Cao FA. Patterns of lymph node metastasis are different in colon and rectal carcinomas. *World J Gastroenterol* 2010; **16**: 5375-5379 [PMID: 21072903 DOI: 10.3748/wjg.v16.i42.5375]

5 **Khatri VP**, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? *J Clin Oncol* 2005; **23**: 8490-8499 [PMID: 16230676 DOI: 10.1200/JCO.2004.00.6155]

6 **Aranda E**, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. *Clin Transl Oncol* 2011; **13**: 162-178 [PMID: 21421461]

7 **Cunningham D**, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; **351**: 337-345 [PMID: 15269313 DOI: 10.1056/NEJMoa033025]

8 **Giantonio BJ**, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. *Ann Oncol* 2006; **17**: 1399-1403 [PMID: 16873427 DOI: 10.1093/annonc/mdl161]

9 **Primrose JN**. Surgery for colorectal liver metastases. *Br J Cancer* 2010; **102**: 1313-1318 [PMID: 20424612 DOI: 10.1038/sj.bjc.6605659]

10 **Kanemitsu Y**, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. *World J Surg* 2008; **32**: 1097-1107 [PMID: 18200429 DOI: 10.1007/s00268-007-9348-0]

11 **Takakura Y**, Miyata Y, Okajima M, Okada M, Ohdan H. Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer. *Colorectal Dis* 2010; **12**: e68-e75 [PMID: 19843115 DOI: 10.1111/j.1463-1318.2009.02070.x]

12 **Pfannschmidt J**, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. *Ann Thorac Surg* 2007; **84**: 324-338 [PMID: 17588454 DOI: 10.1016/j.athoracsur.2007.02.093]

13 **Shibata D**, Paty PB, Guillem JG, Wong WD, Cohen AM. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. *Dis Colon Rectum* 2002; **45**: 795-801 [PMID: 12072633]

14 **Esquivel J**, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. *J Surg Oncol* 2008; **98**: 263-267 [PMID: 18726889 DOI: 10.1002/jso.21053]

15 **Huang PP**, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ. Long-term survival in patients with ovarian metastases from colorectal carcinoma. *Ann Surg Oncol* 1998; **5**: 695-698 [PMID: 9869515]

16 **Erroi F**, Scarpa M, Angriman I, Cecchetto A, Pasetto L, Mollica E, Bettiol M, Ruffolo C, Polese L, Cillo U, D'Amico DF. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. *J Surg Oncol* 2007; **96**: 113-117 [PMID: 17443728 DOI: 10.1002/jso.20803]

17 **Lefevre JH**, Rondelli F, Mourra N, Bennis M, Tiret E, Parc R, Parc Y. Lumboaortic and iliac lymphadenectomy for lymph node recurrence of colorectal cancer: prognostic value of the MSI phenotype. *Ann Surg Oncol* 2008; **15**: 2433-2438 [PMID: 18566862 DOI: 10.1245/s10434-008-0007-y]

18 **Min BS**, Kim NK, Sohn SK, Cho CH, Lee KY, Baik SH. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. *J Surg Oncol* 2008; **97**: 136-140 [PMID: 17963247 DOI: 10.1002/jso.20926]

19 **Timmerman R**, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA* 2010; **303**: 1070-1076 [PMID: 20233825 DOI: 303/11/1070]

20 **Chi A**, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. *Radiother Oncol* 2010; **94**: 1-11 [PMID: 20074823 DOI: S0167-8140(09)00666-5]

21 **Schlijper RC**, Grutters JP, Houben R, Dingemans AM, Wildberger JE, Van Raemdonck D, Van Cutsem E, Haustermans K, Lammering G, Lambin P, De Ruysscher D. What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation? *Cancer Treat Rev* 2014; **40**: 60-67 [PMID: 23768754 DOI: 10.1016/j.ctrv.2013.05.004]

22 **Hellman S**, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; **13**: 8-10 [PMID: 7799047]

23 **Corbin KS**, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. *J Clin Oncol* 2013; **31**: 1384-1390 [PMID: 23460715 DOI: 10.1200/JCO.2012.45.9651]

24 **Rees M**, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. *Ann Surg* 2008; **247**: 125-135 [PMID: 18156932 DOI: 10.1097/SLA.0b013e31815aa2c2]

25 **Pawlik TM**, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. *Ann Surg* 2005; **241**: 715-22, discussion 722-4 [PMID: 15849507]

26 **Nordlinger B**, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. *Cancer* 1996; **77**: 1254-1262 [PMID: 8608500]

27 **Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309-18; discussion 318-21 [PMID: 10493478]

28 **Tomlinson JS**, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007; **25**: 4575-4580 [PMID: 17925551 DOI: 10.1200/JCO.2007.11.0833]

29 **Renaud S**, Falcoz PE, Olland A, Massard G. Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? *Interact Cardiovasc Thorac Surg* 2013; **16**: 68-73 [PMID: 23054908 DOI: 10.1093/icvts/ivs423]

30 **Fuks Z**, Kolesnick R. Engaging the vascular component of the tumor response. *Cancer Cell* 2005; **8**: 89-91 [PMID: 16098459 DOI: 10.1016/j.ccr.2005.07.014]

31 **Hall EJ**, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. *Int J Radiat Oncol Biol Phys* 1993; **25**: 381-385 [PMID: 8420891]

32 **Qiao X**, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. *Lung Cancer* 2003; **41**: 1-11 [PMID: 12826306]

33 **Grutters JP**, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol* 2010; **95**: 32-40 [PMID: 19733410 DOI: 10.1016/j.radonc.2009.08.003]

34 **Verstegen NE**, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJ, Amir MI, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. *Ann Oncol* 2013; **24**: 1543-1548 [PMID: 23425947 DOI: 10.1093/annonc/mdt026]

35 **Puri V**, Crabtree TD, Kymes S, Gregory M, Bell J, Bradley JD, Robinson C, Patterson GA, Kreisel D, Krupnick AS, Meyers BF. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. *J Thorac Cardiovasc Surg* 2012; **143**: 428-436 [PMID: 22169443 DOI: S0022-5223(11)01243-8]

36 **Lagerwaard FJ**, Aaronson NK, Gundy CM, Haasbeek CJ, Slotman BJ, Senan S. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. *J Thorac Oncol* 2012; **7**: 1148-1154 [PMID: 22610256 DOI: 10.1097/JTO.0b013e318252cfef]

37 . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

38 **Andolino DL**, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2011; **81**: e447-e453 [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011]

39 **Bujold A**, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol* 2013; **31**: 1631-1639 [PMID: 23547075 DOI: 10.1200/JCO.2012.44.1659]

40 **Sanuki N**, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda E. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. *Acta Oncol* 2014; **53**: 399-404 [PMID: 23962244 DOI: 10.3109/0284186X.2013.820342]

41 **Takeda A**, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 372-379 [PMID: 23927053 DOI: 10.1111/jgh.12350]

42 **van Laarhoven HW**, Kaanders JH, Lok J, Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, van der Kogel AJ. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. *Int J Radiat Oncol Biol Phys* 2006; **64**: 473-482 [PMID: 16242253 DOI: S0360-3016(05)02374-6]

43 **Romero AM**, Seppenwoolde Y, Verheij J, Dwarkasing RS, Verhoef C, Redekop WK, IJzermans JNM, Nowak PJCM, Levendag PC, Heijmen BJM. Macroscopic and Microscopic Pathologic Findings of Colorectal Liver Metastases Correlated with Magnetic Resonance Imaging to Establish Safety Margins for Stereotactic Body Radiation Therapy. *Int J Radiat Oncol* 2010; **78**: S56

44 **Takeda A**, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. *Radiother Oncol* 2011; **101**: 255-259 [PMID: 21641064 DOI: 10.1016/j.radonc.2011.05.033]

45 **Benson AB**, Grem JL, Saltz L, Bekaii-Saab T, Hunt S, Sharma S, Chan E, Kamel A, Skibber JM, Chen Y, Leong LA, Small W, Choti MA. NCCN Clinical Practice Guideline in Oncology Web site. Colon Cancer. Version 3.2013 ed: National Comprehensive Cancer Network, 2013

46 **Aloia TA**, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. *Arch Surg* 2006; **141**: 460-46; discussion 460-46; [PMID: 16702517 DOI: 10.1001/archsurg.141.5.460]

47 **Lee WS**, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Choi D, Kim SH, Rhim H, Lim HK. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. *J Clin Gastroenterol* 2008; **42**: 945-949 [PMID: 18438208 DOI: 10.1097/MCG.0b013e318064e752]

48 **Folprecht G**, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005; **16**: 1311-1319 [PMID: 15870084 DOI: 10.1093/annonc/mdi246]

49 **Neumann UP**, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. *Dtsch Arztebl Int* 2010; **107**: 335-342 [PMID: 20532128 DOI: 10.3238/arztebl.2010.0335]

50 **Herfarth KK**, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. *Front Radiat Ther Oncol* 2004; **38**: 100-105 [PMID: 15458194]

51 **Wulf J**, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. *Acta Oncol* 2006; **45**: 838-847 [PMID: 16982548 DOI: 10.1080/02841860600904821]

52 **Katz AW**, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. *Int J Radiat Oncol Biol Phys* 2007; **67**: 793-798 [PMID: 17197128 DOI: 10.1016/j.ijrobp.2006.10.025]

53 **Rusthoven KE**, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol* 2009; **27**: 1572-1578 [PMID: 19255321 DOI: 10.1200/JCO.2008.19.6329]

54 **Lee MT**, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA. Phase I study of individualized stereotactic body radiotherapy of liver metastases. *J Clin Oncol* 2009; **27**: 1585-1591 [PMID: 19255313 DOI: 10.1200/JCO.2008.20.0600]

55 **van der Pool AE**, Méndez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, Ijzermans JN. Stereotactic body radiation therapy for colorectal liver metastases. *Br J Surg* 2010; **97**: 377-382 [PMID: 20095016 DOI: 10.1002/bjs.6895]

56 **Rule W**, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. *Ann Surg Oncol* 2011; **18**: 1081-1087 [PMID: 21046264 DOI: 10.1245/s10434-010-1405-5]

57 **Vautravers-Dewas C**, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N, Lartigau E, Mirabel X. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? *Int J Radiat Oncol Biol Phys* 2011; **81**: e39-e47 [PMID: 21377292 DOI: 10.1016/j.ijrobp.2010.12.047]

58 **Scorsetti M**, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. *Int J Radiat Oncol Biol Phys* 2013; **86**: 336-342 [PMID: 23433800 DOI: 10.1016/j.ijrobp.2012.12.021]

59 **White RR**, Avital I, Sofocleous CT, Brown KT, Brody LA, Covey A, Getrajdman GI, Jarnagin WR, Dematteo RP, Fong Y, Blumgart LH, D'Angelica M. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. *J Gastrointest Surg* 2007; **11**: 256-263 [PMID: 17458595 DOI: 10.1007/s11605-007-0100-8]

60 **Reuter NP**, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? *J Gastrointest Surg* 2009; **13**: 486-491 [PMID: 18972167 DOI: 10.1007/s11605-008-0727-0]

61 **Hur H**, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, Cho CH, Ko HK, Lee JT, Kim NK. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. *Am J Surg* 2009; **197**: 728-736 [PMID: 18789428 DOI: 10.1016/j.amjsurg.2008.04.013]

62 **Wu YZ**, Li B, Wang T, Wang SJ, Zhou YM. Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. *World J Gastroenterol* 2011; **17**: 4143-4148 [PMID: 22039331 DOI: 10.3748/wjg.v17.i36.4143]

63 **Aberg T**, Malmberg KA, Nilsson B, Nöu E. The effect of metastasectomy: fact or fiction? *Ann Thorac Surg* 1980; **30**: 378-384 [PMID: 7425716]

64 **Gonzalez M**, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. *Ann Surg Oncol* 2013; **20**: 572-579 [PMID: 23104709 DOI: 10.1245/s10434-012-2726-3]

65 **Onaitis MW**, Petersen RP, Haney JC, Saltz L, Park B, Flores R, Rizk N, Bains MS, Dycoco J, D'Amico TA, Harpole DH, Kemeny N, Rusch VW, Downey R. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. *Ann Thorac Surg* 2009; **87**: 1684-1688 [PMID: 19463577 DOI: 10.1016/j.athoracsur.2009.03.034]

66 **Welter S**, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. *Ann Thorac Surg* 2007; **84**: 203-210 [PMID: 17588413 DOI: 10.1016/j.athoracsur.2007.03.028]

67 **De Giacomo T**, Rendina EA, Venuta F, Ciccone AM, Coloni GF. Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. *Chest* 1999; **115**: 1441-1443 [PMID: 10334166]

68 **Welter S**, Theegarten D, Trarbach T, Maletzki F, Stamatis G, Tötsch M. Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry. *J Thorac Cardiovasc Surg* 2011; **141**: 1218-1222 [PMID: 21163502 DOI: 10.1016/j.jtcvs.2010.08.089]

69 **Shiono S**, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, Tsuta K, Kim YH, Nishiwaki Y, Kodama T, Iwasaki M, Ochiai A. Predictive factors for local recurrence of resected colorectal lung metastases. *Ann Thorac Surg* 2005; **80**: 1040-1045 [PMID: 16122482 DOI: 10.1016/j.athoracsur.2004.12.033]

70 **Wulf J**, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. *Int J Radiat Oncol Biol Phys* 2004; **60**: 186-196 [PMID: 15337555 DOI: 10.1016/j.ijrobp.2004.02.060]

71 **Okunieff P**, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, Schell MC. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. *Acta Oncol* 2006; **45**: 808-817 [PMID: 16982544 DOI: 10.1080/02841860600908954]

72 **Norihisa Y**, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. *Int J Radiat Oncol Biol Phys* 2008; **72**: 398-403 [PMID: 18374506 DOI: 10.1016/j.ijrobp.2008.01.002]

73 **Kim MS**, Yoo SY, Cho CK, Yoo HJ, Choi CW, Seo YS, Kang JK, Lee DH, Hwang DY, Moon SM, Kim MS, Kang HJ, Kim YH. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. *Oncology* 2009; **76**: 212-219 [PMID: 19218825 DOI: 10.1159/000201932]

74 **Rusthoven KE**, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. *J Clin Oncol* 2009; **27**: 1579-1584 [PMID: 19255320 DOI: 10.1200/JCO.2008.19.6386]

75 **Oh D**, Ahn YC, Seo JM, Shin EH, Park HC, Lim do H, Pyo H. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. *Acta Oncol* 2012; **51**: 596-602 [PMID: 22548366 DOI: 10.3109/0284186X.2012.681698]

76 **Ricardi U**, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, Botticella A, Ciammella P, Iftode C, Buffoni L, Ruffini E, Scagliotti GV. Stereotactic body radiation therapy for lung metastases. *Lung Cancer* 2012; **75**: 77-81 [PMID: 21726918 DOI: 10.1016/j.lungcan.2011.04.021]

77 **Inoue T**, Katoh N, Onimaru R, Shirato H. Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence. *Pulm Med* 2012; **2012**: 369820 [PMID: 22848816 DOI: 10.1155/2012/369820]

78 **Widder J**, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? *Radiother Oncol* 2013; **107**: 409-413 [PMID: 23773410 DOI: 10.1016/j.radonc.2013.05.024]

79 **Inoue T**, Oh RJ, Shiomi H, Masai N, Miura H. Stereotactic body radiotherapy for pulmonary metastases. Prognostic factors and adverse respiratory events. *Strahlenther Onkol* 2013; **189**: 285-292 [PMID: 23420546 DOI: 10.1007/s00066-012-0290-1]

80 **Filippi AR**, Badellino S, Guarneri A, Levis M, Botticella A, Mantovani C, Ragona R, Racca P, Buffoni L, Novello S, Ricardi U. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. *Technol Cancer Res Treat* 2014; **13**: 37-45 [PMID: 23819496]

81 **Lencioni R**, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). *Lancet Oncol* 2008; **9**: 621-628 [PMID: 18565793 DOI: 10.1016/S1470-2045(08)70155-4]

82 **Yan TD**, King J, Sjarif A, Glenn D, Steinke K, Al-Kindy A, Morris DL. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. *Ann Surg Oncol* 2007; **14**: 1718-1726 [PMID: 17285398 DOI: 10.1245/s10434-006-9271-x]

83 **Yamakado K**, Inoue Y, Takao M, Takaki H, Nakatsuka A, Uraki J, Kashima M, Kusunoki M, Shimpo H, Takeda K. Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. *Oncol Rep* 2009; **22**: 885-891 [PMID: 19724869]

84 **Chua TC**, Thornbury K, Saxena A, Liauw W, Glenn D, Zhao J, Morris DL. Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. *Cancer* 2010; **116**: 2106-2114 [PMID: 20166209 DOI: 10.1002/cncr.24952]

85 **Figueredo A**, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. *BMC Cancer* 2003; **3**: 26 [PMID: 14529575 DOI: 10.1186/1471-2407-3-26]

86 **Kim MS**, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. *World J Gastroenterol* 2009; **15**: 6091-6095 [PMID: 20027683]

87 **Yeo SG**, Kim DY, Kim TH, Jung KH, Hong YS, Kim SY, Park JW, Choi HS, Oh JH. Curative chemoradiotherapy for isolated retroperitoneal lymph node recurrence of colorectal cancer. *Radiother Oncol* 2010; **97**: 307-311 [PMID: 20667611 DOI: 10.1016/j.radonc.2010.05.021]

88 **Rich T**, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G. Patterns of recurrence of rectal cancer after potentially curative surgery. *Cancer* 1983; **52**: 1317-1329 [PMID: 6192900]

89 **Pilipshen SJ**, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. *Cancer* 1984; **53**: 1354-1362 [PMID: 6692324]

90 **McCall JL**, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. *Int J Colorectal Dis* 1995; **10**: 126-132 [PMID: 7561427]

91 **McDermott FT**, Hughes ES, Pihl E, Johnson WR, Price AB. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. *Br J Surg* 1985; **72**: 34-37 [PMID: 3967128]

92 **Kim MS**, Choi C, Yoo S, Cho C, Seo Y, Ji Y, Lee D, Hwang D, Moon S, Kim MS, Kang H. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. *Jpn J Clin Oncol* 2008; **38**: 695-700 [PMID: 18723850 DOI: 10.1093/jjco/hyn083]

93 **Abusaris H**, Hoogeman M, Nuyttens JJ. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. *Technol Cancer Res Treat* 2012; **11**: 591-597 [PMID: 22568625]

94 **Sahgal A**, Bilsky M, Chang EL, Ma L, Yamada Y, Rhines LD, Létourneau D, Foote M, Yu E, Larson DA, Fehlings MG. Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient. *J Neurosurg Spine* 2011; **14**: 151-166 [PMID: 21184635 DOI: 10.3171/2010.9.SPINE091005]

95 **Sahgal A**, Atenafu EG, Chao S, Al-Omair A, Boehling N, Balagamwala EH, Cunha M, Thibault I, Angelov L, Brown P, Suh J, Rhines LD, Fehlings MG, Chang E. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. *J Clin Oncol* 2013; **31**: 3426-3431 [PMID: 23960179 DOI: 10.1200/JCO.2013.50.1411]

96 **Short S**, Chaturvedi A, Leslie MD. Palliation of symptomatic adrenal gland metastases by radiotherapy. *Clin Oncol (R Coll Radiol)* 1996; **8**: 387-389 [PMID: 8973857]

97 **Oshiro Y**, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. *Am J Clin Oncol* 2011; **34**: 249-253 [PMID: 20498589 DOI: 10.1097/COC.0b013e3181dbb727]

98 **Scorsetti M**, Alongi F, Filippi AR, Pentimalli S, Navarria P, Clerici E, Castiglioni S, Tozzi A, Reggiori G, Mancosu P, Ricardi U. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. *Acta Oncol* 2012; **51**: 618-623 [PMID: 22263925 DOI: 10.3109/0284186X.2011.652738]

99 **Casamassima F**, Livi L, Masciullo S, Menichelli C, Masi L, Meattini I, Bonucci I, Agresti B, Simontacchi G, Doro R. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. *Int J Radiat Oncol Biol Phys* 2012; **82**: 919-923 [PMID: 21300473 DOI: 10.1016/j.ijrobp.2010.11.060]

**P-Reviewers:** Chow J, Tang D, Vinh-Hung V **S-Editor:** Gou SX

**L-Editor: E-Editor:**

**Table 1 Summary of stereotactic body radiotherapy for liver metastasis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study** | **Patients (*n*)(primary sites)** | **Meta (*n*)** | **Institution** | **MFU (mo)** | **Dose (Gy)/fr** | **Time (d)** | **Prescription specification** | **LC (mo)** | **OS (mo)** | **Toxicity** | ***P*-value** |
| Herfarth *et al*[[50](#_ENREF_50)] | P I | CRC (*n =* 18)others (*n =* 14) | 60- | Heidelberg Univ. | 15  | 14-26/1 | 1  | isocenter, PTV surrounded by 80% isodose | 0% (24) | 32% (24) | N MT | *P* < 0.01 |
| 　 | P II |  |  |  | 26/1 | 1  | 81% (24) | 83% (24) |  |
| Wulf *et al*[[51](#_ENREF_51)] | Retro | 39 | CRC (*n =* 23)others (*n =* 28) | Wuerzburg Univ. | 15  | 28-30/3-4 | 2-3 interval | PTV periphery: 65% isodose of maximum | 58% (24) | 81% (24 for all) | N MT | *P =* 0.08 |
| 　 |  | 36-37.5/3 or 26/1 | 82% (24) |
| Katz *et al*[[52](#_ENREF_52)] | Retro | CRC (*n =* 20)others (*n =* 49) | 174 | Rochester Univ. | 15  | 50/5f preferred | 14  | maximum, PTV surrounded by the 80% isodose | 57% (20) | 37% (20) | N MT | 　 |
| Rusthoven *et al*[[53](#_ENREF_53)] | P I/II | CRC (*n =* 20)others (*n =* 49) | 63 | multi-institution | 16  | 36-60/3 | < 14  | isocenter, PTV surrounded by 80%-90% isodose | 92% (24) | 30% (24) | Grade ≥ 3: 2% |
| Lee *et al*[[54](#_ENREF_54)] | P I | CRC (*n =* 40)others (*n =* 28) | - | Princess Margaret Hospital | 11  | 27.7-60/6 (median: 41.8) | > 14  | PTV periphery: 71% isodose of maximum | 71% (12) | 47% (18) | N MT | 　 |
| van der Pool *et al*[[55](#_ENREF_55)] | Retro | CRC (*n =* 20) | 31 | Erasmus Univ. | 26  | 37.5-45/3f preferred | 5-6  | D95 of PTV | 74% (24) | 83% (24) | N MT | 　 |
| Rule *et al*[[56](#_ENREF_56)] | P I | CRC (*n =* 12)others (*n =* 15) | 36 | Texas Southwestern Univ. | 20  | 30/3 | <14  | PTV periphery, 70%-85% isodose of maximum | 59% (24) | 56% (24) | N MT | 　 |
|  | 50/5 | ≤ 17  | 89% (24) | 67% (24) | 　 |
| 　 | 　 |  |  |  | 60/5 | ≤ 17  | 100% (24) | 50% (24) |  | 　 |
| Vautravers-Dewas *et al*[[57](#_ENREF_57)] | Retro | CRC (*n =* 30)others (*n =* 15) | 62 | Centre Oscar Lambret | 14  | 40/3 | 4-17 (mean: 9) | PTV periphery, 80% isodose of the maximum | 86% (12) | 48% (24 for all) | N MT | *P =* 0.07 |
| 　 | 　 |  |  |  | 45/3 | 100% (12) |
| 　 | 　 | CRC (*n =* 30) |  |  |  |  |  |  | 86% (12) |  |  | *P =* 0.07 |
| 　 | 　 | others (*n =* 15) |  |  |  |  |  |  | 100% (12) |  |  |
| Scorsetti *et al*[[58](#_ENREF_58)] | P II | CRC (*n =* 29)others (*n =* 32) | 76 | Humanitas Cancer Center | 12  | 52.5-75/3 | 3 | Mean dose to PTV | 90.6% (24) | 37% (24) | N MT | 　 |

MFU: Median follow up duration; LC: Local control rate; OS: Overall survival rate; P X: Phase X; retro: Retrospective; CRC: Colorectal cancer; fr: Fractions; PTV: Planning target volume; Dx: The dose delivered to x%; N MT: No major toxicity.

**Table 2 Summary of stereotactic body radiotherapy for pulmonary metastasis**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study** | **Patients (*n*)(primary sites)** | **Meta (*n*)** | **Institution** |  **MFU (mo)** | **Dose (Gy)/** | **Time (d)** | **Prescription specification** | **LC (mo)** | **OS (mo)** | **Toxicity** | ***P*-value** |
| Wulf *et al*[[70](#_ENREF_70)] | Retro | CRC (*n =* 4)others (*n =* 37) | 51 | Wuerzburg Univ. | 10  | 30-37.5/3 or 26/1 | 2-3 interval | PTV periphery: 65% isodose of maximum | 80% (24) | 33% (24) | N MT |  |
| Okunieff *et al*[[71](#_ENREF_71)] | Retro | CRC (*n =* 14)others (*n =* 35) | 125 | Rochester Univ. | 19  | 50/10 | 1-5 times per week | Isocenter | 91% (24) | 38% (24) | Grade ≥ 3: 2% |
| Norihisa *et al*[[72](#_ENREF_72)] | Retro | CRC (*n =* 14)others (*n =* 35) | 43 | Kyoto Univ. | 27  | 48-60/4 | 4-18 (med: 12) | Isocenter | 90% (24) | 84.3% (24) | Grade 3 RP: 3% |
| Kim *et al*[[73](#_ENREF_73)] | Retro | CRC (*n =* 13) | 18 | Korea Cancer Center | 28  | 39-51/3 | 3 | PTV periphery: 75%-80% isodose of maximum | 53% (24) | 76% (24) | N MT |  |
| Rusthoven *et al*[[74](#_ENREF_74)] | P I/II | CRC (*n =* 9)others (*n =* 29) | 63 | multi-institution | 15  | 48-60/3 | < 14 | Isocenter, PTV surrounded by 80-90% isodose | 96% (24) | 39% (24) | Grade 3 RP: 8% |
| Takeda *et al*[[44](#_ENREF_44)] | Retro | CRC (*n =* 15) | CRC (*n =* 21) | Ofuna Chuo Hospital | 29  | 50/5 | 5 | PTV periphery: 75%-80% isodose of maximum | 72% (24) | - | N MT | *P* < 0.05 |
| 　 |  | others (*n =* 19) | others (*n =* 23) |  | 15  | 94% (24) | - |
| Oh *et al*[[75](#_ENREF_75)] | Retro | 57 | 67 | Samsung Medical Center | 21  | 50-60/4-5 | - | PTV periphery: 75%-80% isodose of maximum | 92% (24) | 57% (24) | Grade 5 RP: 2% |
| 　 |  |  | CRC,HCC (*n =* 16) |  |  |  |  | 81% (24) |  |  | *P =* 0.01 |
| 　 |  |  | others (*n =* 51) |  |  |  |  |  | 100% (24) |  |  |
| Ricardi *et al*[[76](#_ENREF_76)] | Retro | 61 | 77 | Giovanni Battista Univ. | 20  | 26/1 or36-45/3 | 3 | PTV periphery: 80% isodose of maximum | 89% (24) | 66.5% (24) | Grade 3 RP: 2% |
| Inoue *et al*[[77](#_ENREF_77)] | Retro | 22 | 31 | Hokkaido Univ. | 25  | 48/4 | 4-7 | isocenter | 100% (24) | 80% (24) | N MT |  |
| Widder *et al*[[78](#_ENREF_78)] | Retro | CRC (*n =* 31)others (*n =* 11) | ≥ 65 | Groningen Univ. | 43  | 60/3-8 | - | PTV periphery: adaptedrisk of toxicity | 94% (24) | 86% (24) | - |  |
| Inoue *et al*[[79](#_ENREF_79)] | Retro | CRC (*n =* 37)others (*n =* 50) | ≥ 150 |  Miyakojima IGRT Clinic | 15  | 48/4, 52-60/4 or 50/5 | 4-5 | - | 80% (24) | 47% (24) | Grade 3 RP: 6% grade4 RP: 1% |

MFU: Median follow up duration; LC: Local control rate; OS: Overall survival rate; P X: Phase X; retro: Retrospective; CRC: Colorectal cancer; fr: Fractions; PTV: Planning target volume; Dx: The dose delivered to x%; N MT: No major toxicity; RP: Radiation pneumonitis.